Evidence map›Paper›PMID 22865205›Full record

ArticleJournal of cachexia, sarcopenia and muscle2012

Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia.

Matteo Cesari, Roger A Fielding, Marco Pahor, Bret Goodpaster, Marc Hellerstein, Gabor A van Kan, Stefan D Anker, Seward Rutkove, J Willem Vrijbloed, Maria Isaac and 12 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03955302 (Ultrasound Assessment of Muscle Architecture Before and After the Implementation of a Physical Exercise Regime in the Water in a Frail Elderly Population), which is not on this map. Cited by 145 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03955302 nacompletednot on this mapstarted 2018, after this paper: background citation

Ultrasound Assessment of Muscle Architecture Before and After the Implementation of a Physical Exercise Regime in the Water in a Frail Elderly Population

TypeinterventionalSponsorUniversity of ValenciaRan2018 to 2019Enrolled41ConditionsFrailty SyndromeArmsExercise
3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Matteo CesariGerontopôle and INSERM Unit 1027, Université de Toulouse, Toulouse, France, macesari@gmail.com.
Roger A Fielding
Marco Pahor
Bret Goodpaster
Marc Hellerstein
Gabor A van Kan
Stefan D Anker
Seward Rutkove
J Willem Vrijbloed
Maria Isaac
Yves Rolland
Christine M'rini
Mylène Aubertin-Leheudre
Jesse M Cedarbaum
Mauro Zamboni
Cornell C Sieber
Didier Laurent
William J Evans
Ronenn Roubenoff
John E Morley
Bruno Vellas
International Working Group on Sarcopenia

Funding

University of Florida Older Americans Independence Center (OAIC)P30AG028740 · NIA · UNIVERSITY OF FLORIDA · PI CHRISTIAAN LEEUWENBURGH · 2007 to 2026
$22.8M
NIA NIH HHS P30 AG028740
6 · The paper itself

Abstract

Sarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the results of a recent meeting of the International Working Group on Sarcopenia (a task force consisting of geriatricians and scientists from academia and industry) held on June 7-8, 2011 in Toulouse (France). The meeting was specifically focused at gaining knowledge on the currently available biomarkers (functional, biological, or imaging-related) that could be utilized in clinical trials of sarcopenia and considered the most reliable and promising to evaluate age-related modifications of skeletal muscle. Specific recommendations about the assessment of aging skeletal muscle in older people and the optimal methodological design of studies on sarcopenia were also discussed and finalized. Although the study of skeletal muscle decline is still in a very preliminary phase, the potential great benefits derived from a better understanding and treatment of this condition should encourage research on sarcopenia. However, the reasonable uncertainties (derived from exploring a novel field and the exponential acceleration of scientific progress) require the adoption of a cautious and comprehensive approach to the subject.

Identifiers

PMID22865205
PMCPMC3424187

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.